A Phase 2 Multicenter, Double-blind, Randomized-controlled Study of Abemaciclib (CDK4 and 6 Inhibitor) in Newly Diagnosed RB-proficient Grade 3 Meningioma Participants
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Abemaciclib (Primary)
- Indications Meningioma
- Focus Therapeutic Use
Most Recent Events
- 09 Apr 2025 Planned End Date changed from 1 Mar 2030 to 1 Sep 2030.
- 09 Apr 2025 Planned primary completion date changed from 1 Mar 2030 to 1 Sep 2028.
- 27 Feb 2025 Planned End Date changed from 1 Dec 2031 to 1 Mar 2030.